MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Sticky Platelets
Using platelet reactivity testing to guide antiplatelet therapy after PCI.
By Tarpan Patel, MD; Adam Bress, PharmD; Sahar Ismail, MD; and Adhir Shroff, MD, MPH
Personalizing Oral Antiplatelet Therapy in PCI
A review of the current agents and choosing the right strategy for your patient.
By Hiren Patel, MD; Adam Bress, PharmD; and Adhir Shroff, MD, MPH
Chief Medial Editor's Page
By Ted E. Feldman, MD, FESC, FACC, FSCAI
Chief Medical Editor's Page
Heart-Valve-Surgery.Com Launches Digital Platform to Support Patients With Aortic Stenosis
April 25, 2024—Heart-Valve-Surgery.com, a patient advocacy group for heart valve disease, announced the launch of its Aortic Stenosis Patient Activation Platform, which is an end-to-end digital platform intended to increase awareness and education for aortic stenosis patients.
Edwards’ Pascal Tricuspid Valve Repair System Evaluated in CLASP TR EFS at 1 Year
April 4, 2022—The American College of Cardiology (ACC) announced 1-year follow-up findings from the Edwards CLASP TR EFS, an early feasibility study assessing the safety and performance of Edwards Lifesciences’ investigational Pascal transcatheter tricuspid valve repair system in tricuspid regurgitation.
JenaValve’s Trilogy Heart Valve System Evaluated in First Commercial Implantations in Europe
June 28, 2022—JenaValve Technology, Inc., a developer and manufacturer of transcatheter aortic valve replacement (TAVR) devices, announced results from the first commercial implantations of the Trilogy heart valve system in high-surgical-risk patients with severe symptomatic aortic stenosis (AS) or aortic regurgitation (AR) in Europe.
Transcaval Access and Closure
A promising new route for TAVR and other procedures.
By Robert J. Lederman, MD, and Adam B. Greenbaum, MD
The Perfect Drug-Eluting Stent
Goals for stent, polymer, and drug development.
By Tim A. Fischell, MD, FACC, FSCAI; Dwight Dishmon, MD; Adam Elhaddi, MD; Shadwan Alsafwah, MD; and Santhosh R. Mannem, MD
CroíValve’s Duo Tricuspid Coaptation Valve System Evaluated in TANDEM I Trial in Poland
November 21, 2022—CroíValve recently announced the first-in-human (FIH) permanent implantation procedures of the company’s Duo tricuspid coaptation valve system for the treatment of tricuspid regurgitation (TR).
Boston Scientific to Acquire Penumbra
January 15, 2026—Boston Scientific Corporation and Penumbra, Inc. announced that the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction that values Penumbra at $374 per share, reflecting an enterprise value of approximately $14.5 billion.
Medtronic and GE Healthcare to Collaborate on Outpatient Care
April 28, 2022—GE Healthcare and Medtronic announced a collaboration focused on the unique needs and demand for care at ambulatory surgery centers (ASCs) and office-based labs (OBLs).
Cordis Names Dr. George Adams as Chief Medical Officer
December 10, 2021—Cordis announced that it has named George Adams, MD, as Chief Medical Officer.
Medtronic Reaches Milestones in Studies of CoreValve System
August 29, 2012—Medtronic, Inc. (Minneapolis, MN) announced that it has reached two clinical program milestones for its CoreValve system in the United States.
Abbott’s TriClip and MitraClip Evaluated in Late-Breaking Clinical Science Presentations
October 24, 2023—Abbott announced data from late-breaking presentations of studies evaluating its minimally invasive heart devices in treating mitral and tricuspid valve disease.
Medtronic's CoreValve TAVR System Approved for Patients at High Risk for Surgery
June 12, 2014—Medtronic, Inc. announced US Food and Drug Administration (FDA) approval of its self-expanding CoreValve transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis who are at high risk for surgery. Medtronic advised that the FDA approved the CoreValve system without the need for an independent device advisory panel review because of the exceptionally positive clinical results demonstrated in the High Risk Study of the CoreValve United States Pivotal Trial. Based on the strength of the trial data, the FDA determined that sufficient information was available to evaluate the safety and efficacy of the Medtronic CoreValve system for both extreme-risk and high-risk patient groups without the need for external Advisory Committee panels.
Alternative-Access Results From the Extreme-Risk Study in Medtronic's CoreValve US Pivotal Trial Presented
October 30, 2013—Medtronic, Inc. (Minneapolis, MN) announced results of patients treated with transcatheter aortic valve replacement (TAVR) via alternative access routes as part of the Extreme Risk study within the CoreValve United States pivotal trial.
Cordis Completes MedAlliance Acquisition
October 2, 2023—MedAlliance, a Switzerland-based manufacturer of the Selution SLR sustained sirolimus drug-eluting balloon (DEB), has been acquired by Cordis, closing the transaction that was first announced in October 2022.
Medtronic Harmony TPV’s European Approval Expanded to Treat Congenital Heart Disease
January 6, 2025—Medtronic announced it received CE Mark approval for the Harmony transcatheter pulmonary valve (TPV) system to treat congenital heart disease patients with native or surgically repaired right ventricular outflow tract (RVOT).
OpSens Commences SAFE-TAVI Study for European Approval of SavvyWire
October 26, 2022—OpSens Inc. announced the successful completion of the first cases in the SAFE-TAVI clinical study in Europe, which is evaluating the company’s SavvyWire left ventricular rapid pacing in transcatheter aortic valve replacement (TAVR) procedures in Europe.
